Ted Schroeder

President, Chief Executive Officer, Director

Ted Schroeder currently serves as president, chief executive officer and director of Zavante Therapeutics. Previously, Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, CEO and member of the board of directors until the company’s acquisition by Mallinckrodt Pharmaceuticals in 2014. Under his leadership, Cadence raised more than $400 million from private and public investors, including completion of a successful IPO. Before this, he held several roles at Elan Pharmaceuticals including senior vice president of North American sales and marketing, and vice president and general manager of the hospital products business unit – a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Earlier in his career, Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He previously served on the boards of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Schroeder is a former chair of BIOCOM, the Southern California life sciences trade association. In 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. Schroeder received a bachelor’s degree in management from Rutgers University.